Halozyme Therapeutics, Inc. (NASDAQ: HALO)

Halozyne Therapeutics, Inc., often recognized by its stock symbol HALO, operates within the biopharmaceutical industry. The company specializes in developing and commercializing innovative solutions aimed at enhancing patient experiences and outcomes for both emerging and established therapies.

Halozyne's primary business activities revolve around its unique ENHANZE technology. This proprietary enzyme has the capability to temporarily break down hyaluronan, a naturally occurring carbohydrate that forms a barrier in the subcutaneous space. This allows for the rapid delivery of high-dose, high-volume injectable biologics, as well as small molecules and fluids. The ENHANZE technology has been demonstrated to enable the combination of two therapeutic antibodies in a single injection, and it also facilitates the development of new co-formulation intellectual property.

The company generates revenue through its ENHANZE collaborations with leading pharmaceutical and biotechnology companies, as well as through the commercialization of its own proprietary products. Halozyne's primary products and services include Hylenex Recombinant, a formulation of rHuPH20 that facilitates subcutaneous administration for achieving hydration, increasing the dispersion and absorption of other injected drugs, and improving resorption of radiopaque agents. Additionally, the company offers XYOSTED, a proprietary product for subcutaneous administration of testosterone replacement therapy for adult males with conditions associated with a deficiency or absence of endogenous testosterone. Lastly, Halozyne provides ATRS-1902, a proprietary drug-device combination product for the endocrinology market, designed to deliver a liquid stable formulation of hydrocortisone for adrenal crisis rescue.

Within the industry, Halozyne holds a strong position, boasting collaborations with several pharmaceutical and biotechnology companies. These include Roche, Takeda, Pfizer, Janssen, AbbVie, Lilly, BMS, argenx, and Alexion. These collaborations aim to develop and commercialize products that combine Halozyne's ENHANZE technology with the partners' proprietary compounds. These collaborations have resulted in several approved products, including Herceptin SC, MabThera SC, Tecentriq SC, HYQVIA, and DARZALEX FASPRO.

Halozyne's customer base is diverse, comprising various pharmaceutical and biotechnology companies, healthcare providers, and patients in need of innovative therapeutic solutions. The company's brand names and/or trade names of its products and services include Hylenex Recombinant, XYOSTED, and ATRS-1902. These products and services are designed to provide efficient, convenient, and effective treatment options for various medical conditions.